Key result
Detection of high BCL11B and/or GLG1 expression by immunohistochemistry reached 96% specificity for Ewing sarcoma, outperforming CD99 which was strongly expressed in 88% of Ewing-like sarcomas.
Population
768 tumors representing 21 entities including Ewing-like sarcomas, and a tissue-microarray comprising 174…
Comparison
Immunohistochemical detection of BCL11B and GLG1 vs Conventional immunohistochemical marker CD99
Design
Other
Authors
Loading...
May aid IHC-based Ewing sarcoma diagnosis; leaves open prospective validation before routine clinical use.
Observational (n=768)
Yes
BCL11B and GLG1 offer a fast, simple, and cost-efficient way to diagnose Ewing sarcoma by immunohistochemistry with high specificity, distinguishing it from morphological mimics.
Baldauf et al. (2017) conducted an observational in Ewing sarcoma (n=768). Immunohistochemical detection of BCL11B and GLG1 vs. CD99 was evaluated on Specificity for Ewing sarcoma. Detection of high BCL11B and/or GLG1 expression by immunohistochemistry reached 96% specificity for Ewing sarcoma, outperforming CD99 which was strongly expressed in 88% of Ewing-like sarcomas.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: